Roles of cyclooxygenase-2 and phosphorylated Akt (Thr308) in cardiac hypertrophy regression mediated by left-ventricular unloading

Journal of Thoracic and Cardiovascular Surgery

Volumn 133, Issue 1, 2007, Pages 37-43

  Wohlschlaeger, Jeremias ^a   Schmitz, Klaus Jürgen ^a   Palatty, Jenci ^a   Takeda, Atsushi ^b   Takeda, Nobuakira ^c   Vahlhaus, Christian ^d   Levkau, Bodo ^a   Stypmann, Jörg ^d   Schmid, Christof ^d   Schmid, Kurt Werner ^a   Baba, Hideo Andreas ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b GUNMA PAZ UNIVERSITY   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B;

ADULT; ARTICLE; CELL SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HEART; HEART ASSIST DEVICE; HEART LEFT VENTRICLE; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MORPHOMETRICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REGRESSION ANALYSIS;

ADOLESCENT; ADULT; CARDIOMEGALY; CELL SIZE; CYCLOOXYGENASE 2; HEART FAILURE, CONGESTIVE; HEART-ASSIST DEVICES; HUMANS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 33845775824     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2006.07.042     Document Type: Article

References (27)

1. van E.V., and De Windt L.J. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res 63 (2004) 487-499
2. Rose E.A., Gelijns A.C., Moskowitz A.J., Heitjan D.F., Stevenson L.W., Dembitsky W., et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345 (2001) 1435-1443
3. Frazier O.H., Benedict C.R., Radovancevic B., Bick R.J., Capek P., Springer W.E., et al. Improved left ventricular function after chronic left ventricular unloading. Ann Thorac Surg 62 (1996) 675-681
4. Baba H.A., Grabellus F., August C., Plenz G., Takeda A., Tjan T.D., et al. Reversal of metallothionein expression is different throughout the human myocardium after prolonged left-ventricular mechanical support. J Heart Lung Transplant 19 (2000) 668-674
5. Razeghi P., and Taegtmeyer H. Activity of the Akt/GSK-3beta pathway in the failing human heart before and after left ventricular assist device support. Cardiovasc Res 61 (2004) 196-197
6. Zafeiridis A., Jeevanandam V., Houser S.R., and Margulies K.B. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 98 (1998) 656-662
7. Wohlschlaeger J., Schmitz K.J., Schmid C., Schmid K.W., Keul P., Takeda A., et al. Reverse remodeling following insertion of left ventricular assist devices (LVAD): a review of the morphological and molecular changes. Cardiovasc Res 68 (2005) 376-386
8. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 99 (2002) 13926-13931
9. Smith W.L., Garavito R.M., and DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271 (1996) 33157-33160
10. Schmedtje Jr. J.F., Ji Y.S., Liu W.L., DuBois R.N., and Runge M.S. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272 (1997) 601-608
11. Torre-Amione G., Kapadia S., Lee J., Durand J.B., Bies R.D., Young J.B., et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93 (1996) 704-711
12. Wong S.C., Fukuchi M., Melnyk P., Rodger I., and Giaid A. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation 98 (1998) 100-103
13. Liu W., Reinmuth N., Stoeltzing O., Parikh A.A., Tellez C., Williams S., et al. Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res 63 (2003) 3632-3636
14. Toker A., and Cantley L.C. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387 (1997) 673-676
15. Leng J., Han C., Demetris A.J., Michalopoulos G.K., and Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 38 (2003) 756-758
16. Dorn G.W., and Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115 (2005) 527-537
17. LaPointe M.C., Mendez M., Leung A., Tao Z., and Yang X.P. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol 286 (2004) H1416-H1424
18. Zhang Z., Vezza R., Plappert T., McNamara P., Lawson J.A., Austin S., et al. COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ Res 92 (2003) 1153-1161
19. Delgado III R.M., Nawar M.A., Zewail A.M., Kar B., Vaughn W.K., Wu K.K., et al. Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation 109 (2004) 1428-1433
20. Razeghi P., Bruckner B.A., Sharma S., Youker K.A., Frazier O.H., and Taegtmeyer H. Mechanical unloading of the failing human heart fails to activate the protein kinase B/Akt/glycogen synthase kinase-3beta survival pathway. Cardiology 100 (2003) 17-22
21. Baba H.A., Stypmann J., Grabellus F., Kirchhof P., Sokoll A., Schafers M., et al. Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res 59 (2003) 390-399
22. Lecomte M., Laneuville O., Ji C., DeWitt D.L., and Smith W.L. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 269 (1994) 13207-13215
23. Patrono C., Coller B., Dalen J.E., FitzGerald G.A., Fuster V., Gent M., et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119 (2001) 39S-63S
24. Tegeder I., Pfeilschifter J., and Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15 (2001) 2057-2072
25. Capone M.L., Tacconelli S., Sciulli M.G., Grana M., Ricciotti E., Minuz P., et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109 (2004) 1468-1471
26. Tessner T.G., Muhale F., Riehl T.E., Anant S., and Stenson W.F. Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest 114 (2004) 1676-1685
27. Han C., and Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 280 (2005) 24053-24063